ORUM Asset Resilience Ratio
ORUM asset resilience ratio. ORUM (475830) has an Asset Resilience Ratio of 51.51% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ORUM liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ORUM (2022–2025)
Asset resilience ratio of ORUM from 2022 to 2025. This chart shows how ORUM's Asset Resilience Ratio has changed over time. Read ORUM (475830) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ORUM's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of ORUM.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩161.13 Billion | 51.51% |
| Total Liquid Assets | ₩161.13 Billion | 51.51% |
Asset Resilience Insights
- Very High Liquidity: ORUM maintains exceptional liquid asset reserves at 51.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ORUM Industry Peers by Asset Resilience Ratio
Compare ORUM's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
ORUM Asset Resilience Ratio by Year (2022–2025)
ORUM asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for ORUM.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.91% | ₩128.54 Billion ≈ $87.11 Million |
₩169.32 Billion ≈ $114.75 Million |
-0.60pp |
| 2024-12-31 | 76.51% | ₩117.70 Billion ≈ $79.76 Million |
₩153.84 Billion ≈ $104.25 Million |
-1.78pp |
| 2023-12-31 | 78.29% | ₩126.66 Billion ≈ $85.83 Million |
₩161.78 Billion ≈ $109.64 Million |
+21.51pp |
| 2022-12-31 | 56.78% | ₩12.09 Billion ≈ $8.19 Million |
₩21.28 Billion ≈ $14.42 Million |
-- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more